The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

May. 16, 2017
Applicant:

Shanghai Pharmaexplorer Co., Ltd., Shanghai, CN;

Inventors:

Yizhen Yang, Shanghai, CN;

Shiyong Gong, Shanghai, CN;

Lijuan Hao, Shanghai, CN;

Jian Wu, Shanghai, CN;

Xinxiu Yang, Shanghai, CN;

Qin Zhong, Shanghai, CN;

Shaoping Hu, Shanghai, CN;

Stewart Leung, Shanghai, CN;

Qing Duan, Shanghai, CN;

Lile Liu, Shanghai, CN;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); C12N 15/85 (2006.01); C07K 16/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 39/395 (2013.01); C07K 16/065 (2013.01); C07K 16/24 (2013.01); C12N 15/85 (2013.01); G01N 33/68 (2013.01); G01N 33/6869 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12N 2015/8518 (2013.01); G01N 2333/5437 (2013.01);
Abstract

The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.


Find Patent Forward Citations

Loading…